Share-based Payment Arrangement, Expense of Inhibikase Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Inhibikase Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,525,206, a 2957% increase year-over-year.
  • Inhibikase Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $18,684,606, a 5172% increase year-over-year.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,140,617, a 1528% increase from 2023.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $500,148, a 9.2% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $458,147, a 70% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Inhibikase Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $18,684,606 $4,525,206 +$4,377,182 +2957% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $14,307,424 $4,208,742 +$4,178,045 +13611% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $10,129,379 $2,042,196 +$1,988,762 +3722% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $8,140,617 $7,908,462 +$7,786,213 +6369% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $354,404 $148,024 +$18,243 +14% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $336,161 $30,697 -$94,148 -75% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $430,309 $53,434 -$69,839 -57% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $500,148 $122,249 +$21,886 +22% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $478,262 $129,781 +$27,993 +28% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $450,269 $124,845 -$7,922 -6% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $458,191 $123,273 +$44 +0.04% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $458,147 $100,363 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $101,788 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $132,767 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $123,229 -$467,895 -79% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q1 2021 $591,124 +$451,366 +323% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q1 2020 $139,758 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1

Inhibikase Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,140,617 +$7,640,469 +1528% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $500,148 +$42,001 +9.2% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $458,147 -$1,073,729 -70% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $1,531,876 +$958,181 +167% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $573,695 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.